IBN SINA Pharmaceuticals has decided to set up a subsidiary company for its natural medicine section to comply with the legal requirements of the Directorate General of Drug Administration (DGDA), Bangladesh.
To be called IBN SINA Natural Medicine, the company will have a paid-up capital of Tk 12 crore, IBN Sina said the posting on the Dhaka Stock Exchange website on Sunday.
The news lifted the stock price of IBN Sina Pharma, which closed the day at Tk 259.1, up 6.2 per cent from the previous trading session.
The new project will be based in Shafipur, Gazipur, with the totalinvestment to come from its own fund subject to completion of all regulatory formalities and approval of the concerned regulatory authorities.
Details of the new company will be shared after approval from all regulators, said Md Shahid Farooqui, company secretary of IBN SINA.
Founded in 1983, Ibn Sina Pharma operates as an enterprise of the IBN SINA Trust.
Its manufacturing plants are divided into two parts: pharmaceutical and natural medicine.
The company manufactures solid dosage forms including tablets and capsule, parenteral products (ampoules, vials), liquid dosage forms including syrup, solutions, suspensions and powder for suspension; sterile ophthalmic products, cream, ointments, gel and sachet, etc.A few of the products are exported to 10 countries.
IBN Sina Pharma saw its profit soar 16.7 per cent year-on-year to Tk 39.3 crore in its 2019-20 financial year.
The company announced a 38.5 per cent cash dividend for the year, up from 30 per cent a year earlier.
Between July and September, its profit leapt 14.6 per cent year-on-year to Tk 10.2 crore.
The company’s paid-up capital is Tk 31 crore and the authorised capital Tk 50 crore.